Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q3 2024 Earnings Presentation
30 slides from Nanologica Ab's earnings presentation, Nov 8, 2024
Slide 1: Interim Report Q3 2024
INTERIM REPORT Q3 2024 N A N O LO G I C A A B ( PU B L )
Slide 2: Financial Summary and Events
FINANCIAL SUMMARY • Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period to SEK 7,822 thousand (1,368) • Operating loss for the quarter amounted to SEK -22,203 thousand (-10,292) and for the nine-month period to SEK -47,365 thousand (-34,324) • Loss before
Slide 3: CEO Comment
CEO COMMENT During the third quarter, we received our first recurring order for NLAB Saga® at a value of SEK 3.7 million from a customer in China. After the end of the quarter, we also received a supplementary order worth SEK 1.9 million from this customer, who is a producer of the fast-growing drug
Slide 4: CEO Comment (continued)
methodically build up our sales. The issue also strengthens our financial position so that we can win customers' confidence in us as a long-term supplier. The fact that many existing and new owners share my strong belief in the company is very gratifying as we are now intensifying our sales efforts
Slide 5: This is Nanologica
THIS IS NANOLOGICA Better and cheaper medicine to a larger number of patients Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, we have developed a
Slide 6: Five Reasons to Invest in Nanologica
FIVE REASONS TO INVEST IN NANOLOGICA By developing chromatography products that enable pharmaceutical manufacturers to streamline their production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access
Slide 7: Summary of the Third Quarter
SUMMARY OF THE THIRD QUARTER thousand to analytical chromatography and SEK During the quarter, several large-scale batches of 338 thousand to application development and silica were produced and approved, after which other services. For the nine-month period, net products were delivered to customers
Slide 8: Investments, Liquidity and Financial Position
deductions amounting to TSEK 336,708 and the flow. The agreement is an order and a refund can parent company had tax loss deduction only be made if the supplier grossly abuses its amounting to TSEK 341,749. The tax loss commitment, shows deficiencies in quality, in deductions may be activated when t
Slide 9: Rights Issue and Extraordinary General Meeting
RIGHTS ISSUE EXTRAORDINARY GENERAL On August 29, the board of directors resolved to MEETING SEPTEMBER 23, 2024 carry out a fully underwritten rights issue of On September 23, 2024, Nanologica held an approximately SEK 99.4 million, which was Extraordinary General Meeting at which among approved by a
Slide 10: Patents, Partnerships and Shareholders
PATENTS Shareholders as of September 30, 2024 In accordance with the company's IP policy, Share Shareholder Shares Nanologica continuously revises the commercial % values of its patents and trademarks. Only Flerie Invest AB 17,298,113 39.2 patents and trademarks that are deemed to be Swedbank Robur
Slide 11: Annual General Meeting, Future Prospects, Risks and Uncertainties
ANNUAL GENERAL MEETING group's risk management is to identify, prevent, The Annual General Meeting is planned to be measure, control and limit the risks in the held on May 22, 2025 in Stockholm. All AGM business. Significant risks are the same for the documents, including the Annual Report, will be
Slide 12: Auditors Review and Assurance
currently hedged any exchange rates. Climate change poses a major risk to humanity from a global perspective, with financial risks as a result. At present, however, Nanologica assesses that climate risks do not have, or will have in the near future, a significant impact on the company's financial pe
Slide 13: Financial Reports and Notes
FINANCIAL REPORTS AND NOTES
Slide 14: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT 2024 2023 2024 2023 2023 Amounts in TSEK Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Net sales 611 342 7 822 1 368 1 443 Change in inventories, finished goods -2 328 -230 12 632 623 2 080 Capitalized work for own use 0 0 0 2 362 3 229 Other operating income 171 63
Slide 15: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET 2024 2023 2023 Amounts in TSEK Sep 30 Sep 30 Dec 31 ASSETS Fixed assets Intangible fixed assets Capitalized expenditure for research and development and similar 16 855 21 942 21 809 Concessions, patents, licenses, trademarks and similar rights 0 1 469 1 332 Tangible fixed
Slide 16: Consolidated Statement of Changes in Equity
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 2024 2023 2024 2023 2023 Amounts in TSEK Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Total equity at the beginning of the period 14 455 46 394 -1 898 73 158 73 158 0 Profit/loss for the period -23 701 -11 554 -51 596 -38 318 -75 157 Other comprehensi
Slide 17: Consolidated Cash Flow Statement
CONSOLIDATED CASH FLOW STATEMENT 2024 2023 2024 2023 2023 Amounts in TSEK Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Operating activities Operating profit/loss -22 203 -10 292 -47 365 -34 324 -69 963 Adjustment for items not affecting cash flow 5 163 3 730 11 706 10 617 18 959 Write-down of o
Slide 18: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664-5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is F
Slide 19: Segment Information
Nanologica currently has one operating segment in the group; Chromatography. Up until 2023, there was a second operating segment, Drug Development, in which operations were discontinued at the end of 2023. Ongoing external collaborations based on the company's drug delivery technology platform are c
Slide 20: Segment Information and Net Sales Composition
2023 Jan - Sep Amounts in TSEK Chroma DD Corp Function Total Net sales 1 369 0 0 1 369 Raw materials, consumables and change in inventories -2 011 -23 0 -2 034 Gross profit -642 -23 0 -666 Other operating items -19 319 -6 121 -8 218 -33 658 Operating profit/loss -19 961 -6 145 -8 218 -34 324 Net fin
Slide 21: Inventories and Financial Assets Notes
NOTE 6 INVENTORIES 2024 2023 2023 Amounts in TSEK Sep 30 Sep 30 Dec 31 Raw materials 131 131 131 Semi-finished products and production in progress 645 146 2 728 Finished products 18 577 1 291 114 Total 19 353 1 568 2 973 NOTE 7 INFORMTATION ON FINANCIAL ASSETS AND LIABILITIES For assets and liabilit
Slide 22: Related Party Transactions and Events After Quarter
Transactions during the third quarter • Costs for loans from Flerie AB amounted to SEK 1,296 thousand during the quarter and refer to costs for interest and commitment fees. • Sales of analytical columns to Nanghavi Chromatography Solutions amounted to SEK 42 thousand during the quarter. NOTE 10 EVE
Slide 23: Alternative Performance Measures
Equity per share* Equity divided by the number of shares outstanding at the end of the period. Average number of shares during the period Calculated as an average of the number of ordinary shares outstanding during the reporting period on a daily basis. * Derivation of alternative performance measur
Slide 24: Group Quarterly Data
GROUP QUARTERLY DATA Amounts in TSEK unless otherwise stated 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 Statement of comprehensive income Net sales 611 2 174 5 037 75 342 672 355 674 Total operating expenses -20 656 -24 938 -22 453 -38 265 -10 467 -15 676 -12 801 -15 326 Operati
Slide 25: Income Statement for the Parent Company
INCOME STATEMENT FOR THE PARENT COMPANY 2024 2023 2024 2023 2023 Amounts in TSEK Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Net sales 611 342 7 822 1 368 1 443 Change in inventories, finished goods -2 328 -230 12 632 623 2 080 Capitalized work for own use 0 0 0 2 362 3 229 Other operating inc
Slide 26: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2024 2023 2023 Amounts in TSEK Sep 30 Sep 30 31 Dec ASSETS Fixed assets Intangible assets Capitalized expenditure for research and development and similar 19 306 28 567 27 391 Concessions, patents, licenses, trademarks and similar rights 0 1 469 1 332 Total intan
Slide 27: Balance Sheet for the Parent Company (equity and liabilities)
BALANCE SHEET FOR THE PARENT COMPANY 2024 2023 2023 Amounts in TSEK Sep 30 Sep 30 31 Dec EQUITY AND LIABILITIES Equity Share capital 4 418 14 821 14 821 Fund for development expenditure 375 6 018 748 Total restricted equity 4 792 20 839 15 569 Non-restricted equity Share premium reserve 348 898 308
Slide 28: Statement of Changes in Equity for the Parent Company
STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY 2024 2023 2024 2023 2023 Amounts in TSEK Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Total equity at the beginning of the period 10 325 41 730 -6 940 68 840 68 840 Share capital -10 403 0 -10 403 0 0 Non registered share capital 10 403 0 0
Slide 29: Cash Flow Statement for the Parent Company
CASH FLOW STATEMENT FOR THE PARENT COMPANY 2024 2023 2024 2023 2023 Amounts in TSEK Jul - Sep Jul - Sep Jan - Sep Jan - Sep Jan - Dec Operating activities Operating profit/loss -22 336 -10 430 -47 745 -34 799 -70 599 Adjustment for items not affecting cash flow 4 407 3 139 10 511 8 843 16 594 Write-
Slide 30: Nanologica AB (publ) contact details
Nanologica AB (publ) Forskargatan 20 G SE-151 36 Södertälje, Sweden Ph: +46-8-410 749 49 www.nanologica.com